FY2028 Earnings Forecast for PROF Issued By Raymond James

Profound Medical Corp. (NASDAQ:PROF - Free Report) - Equities research analysts at Raymond James issued their FY2028 earnings estimates for shares of Profound Medical in a report released on Thursday, November 7th. Raymond James analyst R. Sarugaser forecasts that the company will post earnings of $2.96 per share for the year. The consensus estimate for Profound Medical's current full-year earnings is ($1.10) per share.

Profound Medical (NASDAQ:PROF - Get Free Report) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.28) EPS for the quarter, meeting the consensus estimate of ($0.28). Profound Medical had a negative net margin of 349.41% and a negative return on equity of 80.99%. The firm had revenue of $2.23 million during the quarter, compared to analyst estimates of $2.50 million. During the same quarter in the prior year, the firm earned ($0.35) EPS.

Several other research analysts have also commented on PROF. Lake Street Capital began coverage on Profound Medical in a research report on Tuesday, July 23rd. They issued a "buy" rating and a $16.50 price target for the company. Stifel Nicolaus upgraded shares of Profound Medical from a "hold" rating to a "buy" rating and increased their price target for the stock from $9.00 to $12.00 in a report on Tuesday, July 16th.

Profound Medical Price Performance

Shares of PROF traded down $0.59 during mid-day trading on Monday, reaching $8.16. The stock had a trading volume of 46,211 shares, compared to its average volume of 40,798. Profound Medical has a 12 month low of $7.11 and a 12 month high of $11.69. The company has a debt-to-equity ratio of 0.10, a quick ratio of 7.42 and a current ratio of 8.61. The firm has a market cap of $201.24 million, a price-to-earnings ratio of -6.53 and a beta of 0.83. The business has a fifty day moving average of $7.82 and a 200 day moving average of $8.45.

Institutional Trading of Profound Medical

A number of institutional investors and hedge funds have recently bought and sold shares of PROF. Raymond James Trust N.A. acquired a new position in Profound Medical in the 2nd quarter valued at $88,000. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Profound Medical in the 3rd quarter valued at about $612,000. Thompson Davis & CO. Inc. raised its stake in Profound Medical by 9.0% during the second quarter. Thompson Davis & CO. Inc. now owns 74,800 shares of the company's stock worth $628,000 after purchasing an additional 6,150 shares during the period. Royce & Associates LP grew its stake in shares of Profound Medical by 0.6% during the 3rd quarter. Royce & Associates LP now owns 569,298 shares of the company's stock valued at $4,529,000 after buying an additional 3,500 shares during the period. Finally, Gagnon Advisors LLC raised its holdings in Profound Medical by 10.0% in the first quarter. Gagnon Advisors LLC now owns 747,226 shares of the company's stock valued at $6,374,000 after buying an additional 67,930 shares during the period. 47.86% of the stock is currently owned by hedge funds and other institutional investors.

About Profound Medical

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.